FDA
approval
· 2022-09-23
FDA Approved: ENJAYMO — Supplemental Application (Recordati Rare Diseases, Inc.)
Summary
FDA approved a supplemental application for ENJAYMO (sutimlimab-jome) filed by Recordati Rare Diseases, Inc., approving changes described in the supplemental su…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for ENJAYMO (SUTIMLIMAB-JOME)